Longitudinal analysis of serum-derived extracellular vesicle RNA to monitor dacomitinib treatment response in EGFR-amplified recurrent glioblastoma patients.

Autor: Yekula A; Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA., Hsia T; Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA., Kitchen RR; Exosome Diagnostics, Inc., a Bio-Techne Brand, Waltham, Massachusetts, USA., Chakrabortty SK; Exosome Diagnostics, Inc., a Bio-Techne Brand, Waltham, Massachusetts, USA., Yu W; Exosome Diagnostics, Inc., a Bio-Techne Brand, Waltham, Massachusetts, USA., Batool SM; Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA., Lewis B; Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA., Szeglowski AJ; Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA., Weissleder R; Center for Systems Biology, Massachusetts General Hospital, Boston, Massachusetts, USA., Lee H; Center for Systems Biology, Massachusetts General Hospital, Boston, Massachusetts, USA., Chi AS; Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts, USA., Batchelor T; Department of Neurology, Brigham and Women's Hospital, Boston, Massachusetts, USA., Carter BS; Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA., Breakefield XO; Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts, USA., Skog J; Exosome Diagnostics, Inc., a Bio-Techne Brand, Waltham, Massachusetts, USA., Balaj L; Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.

Publikováno v: Neuro-oncology advances [Neurooncol Adv] 2023 Sep 04; Vol. 5 (1), pp. vdad104. Date of Electronic Publication: 2023 Sep 04 (Print Publication: 2023).

Exosome based analysis for Space Associated Neuro-Ocular Syndrome and health risks in space exploration.

Autor: Chakrabortty SK; Exosome Diagnostics, a Bio-Techne brand, Waltham, MA, USA., Khodor YL; Exosome Diagnostics, a Bio-Techne brand, Waltham, MA, USA., Kitchen RR; Exosome Diagnostics, a Bio-Techne brand, Waltham, MA, USA., Miller DL; Exosome Diagnostics, a Bio-Techne brand, Waltham, MA, USA., Babcock KM; Exosome Diagnostics, a Bio-Techne brand, Waltham, MA, USA., Manning KS; Exosome Diagnostics, a Bio-Techne brand, Waltham, MA, USA., Lang SP; Exosome Diagnostics, a Bio-Techne brand, Waltham, MA, USA., Tadigotla V; Exosome Diagnostics, a Bio-Techne brand, Waltham, MA, USA., Yu W; Exosome Diagnostics, a Bio-Techne brand, Waltham, MA, USA., Bershad E; Baylor College of Medicine, Houston, TX, USA., Skog J; Exosome Diagnostics, a Bio-Techne brand, Waltham, MA, USA. johan.skog@bio-techne.com., Zanello S; KBR, NASA Johnson Space Center, Houston, TX, USA.

Publikováno v: NPJ microgravity [NPJ Microgravity] 2022 Sep 14; Vol. 8 (1), pp. 40. Date of Electronic Publication: 2022 Sep 14.

Exploring Predictors of Response to Dacomitinib in EGFR -Amplified Recurrent Glioblastoma.

Autor: Chi AS; Massachusetts General Hospital and Harvard Medical School, Boston, MA., Cahill DP; Massachusetts General Hospital and Harvard Medical School, Boston, MA., Reardon DA; Dana-Farber/Brigham and Women's Cancer Center and Harvard Medical School, Boston, MA., Wen PY; Dana-Farber/Brigham and Women's Cancer Center and Harvard Medical School, Boston, MA., Mikkelsen T; Ontario Brain Institute, Toronto, Ontario, Canada.; Henry Ford Hospital, Detroit, MI., Peereboom DM; Cleveland Clinic, Cleveland, OH., Wong ET; Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA., Gerstner ER; Massachusetts General Hospital and Harvard Medical School, Boston, MA., Dietrich J; Massachusetts General Hospital and Harvard Medical School, Boston, MA., Plotkin SR; Massachusetts General Hospital and Harvard Medical School, Boston, MA., Norden AD; Dana-Farber/Brigham and Women's Cancer Center and Harvard Medical School, Boston, MA., Lee EQ; Dana-Farber/Brigham and Women's Cancer Center and Harvard Medical School, Boston, MA., Nayak L; Dana-Farber/Brigham and Women's Cancer Center and Harvard Medical School, Boston, MA., Tanaka S; Massachusetts General Hospital and Harvard Medical School, Boston, MA., Wakimoto H; Massachusetts General Hospital and Harvard Medical School, Boston, MA., Lelic N; Massachusetts General Hospital and Harvard Medical School, Boston, MA., Koerner MV; Massachusetts General Hospital and Harvard Medical School, Boston, MA., Klofas LK; Massachusetts General Hospital and Harvard Medical School, Boston, MA., Bertalan MS; Massachusetts General Hospital and Harvard Medical School, Boston, MA., Arrillaga-Romany IC; Massachusetts General Hospital and Harvard Medical School, Boston, MA., Betensky RA; Harvard School of Public Health, Boston, MA., Curry WT; Massachusetts General Hospital and Harvard Medical School, Boston, MA., Borger DR; Massachusetts General Hospital and Harvard Medical School, Boston, MA., Balaj L; Massachusetts General Hospital and Harvard Medical School, Boston, MA., Kitchen RR; Exosome Diagnostics, Waltham, MA., Chakrabortty SK; Exosome Diagnostics, Waltham, MA., Valentino MD; Exosome Diagnostics, Waltham, MA., Skog J; Exosome Diagnostics, Waltham, MA., Breakefield XO; Massachusetts General Hospital and Harvard Medical School, Boston, MA., Iafrate AJ; Massachusetts General Hospital and Harvard Medical School, Boston, MA., Batchelor TT; Massachusetts General Hospital and Harvard Medical School, Boston, MA.

Publikováno v: JCO precision oncology [JCO Precis Oncol] 2020 Jun 08; Vol. 4. Date of Electronic Publication: 2020 Jun 08 (Print Publication: 2020).